Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression (2023)
Journal Article
Atallah, N. M., Haque, M., Quinn, C., Toss, M. S., Makhlouf, S., Ibrahim, A., Green, A. R., Alsaleem, M., Rutland, C. S., Allegrucci, C., Mongan, N. P., & Rakha, E. (2023). Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression. European Journal of Cancer, 195, Article 113371. https://doi.org/10.1016/j.ejca.2023.113371

Background: Breast cancer (BC) expressing low levels of human epidermal growth factor receptor 2 (HER2 Low) is an emerging category that needs further refining. This study aims to provide a comprehensive clinico-pathological and molecular profile of... Read More about Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression.

Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer (2023)
Journal Article
Lashen, A. G., Toss, M. S., Wootton, L., Green, A. R., Mongan, N. P., Madhusudan, S., & Rakha, E. (2023). Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer. Histopathology, 83(3), 414-425. https://doi.org/10.1111/his.14960

Background: Polo-like kinase-1 (PLK1) plays a crucial role in cell cycle progression,and it is considered a potential therapeutic target in many cancers. Although the role of PLK1 is well established in triple negative breast cancer (TNBC) as an onco... Read More about Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer.

Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods (2022)
Journal Article
Lashen, A., Toss, M. S., Green, A. R., Mongan, N. P., & Rakha, E. (2022). Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods. Histopathology, 81(6), 786-798. https://doi.org/10.1111/his.14781

Background: Ki67 reflects the proliferation activity in breast cancer (BC). However, an optimal method for its assessment in clinical settings has yet to be robustly defined. In this study, we compared several methods to score Ki67 to identify a reli... Read More about Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods.

Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer (2022)
Journal Article
Kariri, Y., Toss, M. S., Alsaleem, M., Elsharawy, K. A., Joseph, C., Mongan, N. P., Green, A. R., & Rakha, E. A. (2022). Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer. Breast Cancer Research and Treatment, 192(3), 529-539. https://doi.org/10.1007/s10549-022-06531-5

Background
The Ubiquitin-conjugating enzyme 2C (UBE2C) is essential for the ubiquitin–proteasome system and is involved in cancer cell migration and apoptosis. This study aimed to determine the prognostic value of UBE2C in invasive breast cancer (BC... Read More about Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.

A novel prognostic two-gene signature for triple negative breast cancer (2020)
Journal Article
Alsaleem, M. A., Ball, G., Toss, M. S., Raafat, S., Aleskandarany, M., Joseph, C., Ogden, A., Bhattarai, S., Rida, P. C. G., Khani, F., Davis, M., Elemento, O., Aneja, R., Ellis, I. O., Green, A., Mongan, N. P., & Rakha, E. (2020). A novel prognostic two-gene signature for triple negative breast cancer. Modern Pathology, 33, 2208–2220. https://doi.org/10.1038/s41379-020-0563-7

The absence of a robust risk stratification tool for triple negative breast cancer (TNBC) underlies imprecise and non-selective treatment of these patients with cytotoxic chemotherapy. This study aimed to interrogate transcriptomes of TNBC resected s... Read More about A novel prognostic two-gene signature for triple negative breast cancer.

Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers (2020)
Journal Article
Janssen, E. A., Ogden, A., Bhattarai, S., Sahoo, B., Mongan, N. P., Alsaleem, M., Green, A. R., Aleskandarany, M., Ellis, I. O., Pattni, S., Li, B., Moreno, C. S., Krishnamurti, U., Janssen, E. A., Jonsdottir, K., Rakha, E., Rida, P., & Aneja, R. (2020). Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. Scientific Reports, 10(1), Article 3009. https://doi.org/10.1038/s41598-020-59514-1

© 2020, The Author(s). Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) have been investigated as triple-negative breast cancer (TNBC) biomarkers. Reduced EGFR levels can be compensated by increases in HER3;... Read More about Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers.

The prognostic significance of wild type isocitrate dehydrogenase 2 (IDH2) in breast cancer (2019)
Journal Article
Aljohani, A. I., Toss, M. S., Kurozumi, S., Joseph, C., Aleskandarany, M. A., Miligy, I. M., Ansari, R. E., Mongan, N. P., Ellis, I. O., Green, A. R., & Rakha, E. (2020). The prognostic significance of wild type isocitrate dehydrogenase 2 (IDH2) in breast cancer. Breast Cancer Research and Treatment, 179(1), 79–90. https://doi.org/10.1007/s10549-019-05459-7

Background: Lymphovascular invasion (LVI) is a prerequisite step in breast cancer (BC) metastasis. We have previously identified wild type isocitrate dehydrogenase 2 (IDH2) as a key putative driver of LVI. Thus, we explored the prognostic significanc... Read More about The prognostic significance of wild type isocitrate dehydrogenase 2 (IDH2) in breast cancer.